Abstract
Background: Polycystic ovary syndrome (PCOS) is the commonest endocrinopathy resulting in anovulatory infertility in young women as in recent years have seen a significant rise in women presenting with PCOS . Despite wide acceptance of clomiphene citrate (CC) as the first-line drug for ovulation induction in women with polycystic ovaries (PCOS), a significant proportion of women do not respond to this treatment. In addition, CC use is known to have several disadvantages, including a discrepancy between ovulation and conception rates. Recent studies have suggested that letrozole, an aromatase inhibitor, can be used for ovulation induction and is associated with higher pregnancy rates and less complications than CC treatment in women with PCOs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: American Journal of Medical and Clinical Research & Reviews
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
